Patents by Inventor Jinhwa Lee

Jinhwa Lee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250140792
    Abstract: A rechargeable lithium battery including a positive electrode, and the positive electrode includes a positive electrode current collector, and a positive electrode active material layer on the positive electrode current collector, wherein the positive electrode active material layer includes a first positive electrode active material and a second positive electrode active material, the first positive electrode active material includes lithium nickel-based composite oxide and includes secondary particles composed of a plurality of primary particles, and an average particle diameter (D50) of the secondary particles is about 9 ?m to about 25 ?m, the second positive electrode active material includes lithium nickel-based composite oxide and comprises single particles, and an average particle diameter (D50) of the single particles is about 0.5 ?m to about 5 ?m.
    Type: Application
    Filed: October 25, 2024
    Publication date: May 1, 2025
    Inventors: Jinhwa KIM, Minhan KIM, Soonrewl LEE, Jihyun SEOG
  • Patent number: 11834467
    Abstract: The present disclosure provides a compound of Formula (I) or pharmaceutically acceptable salts thereof, a composition comprising the compound, methods of using the compound for the treatment of various disorders associated with HPK1, and methods of preparing these compounds.
    Type: Grant
    Filed: September 27, 2021
    Date of Patent: December 5, 2023
    Assignee: 1ST Biotherapeutics, Inc.
    Inventors: Jinhwa Lee, Suyeon Jo, Keonseung Lim, A Yeong Park, Gadhe Changdev Gorakshnath, Hwajung Nam, Yeonguk Jeon, Yejin Hwang, Jae Eun Kim, Misoon Kim, Seung Mook Lim
  • Publication number: 20230365557
    Abstract: The present disclosure provides a compound of Formula (I) or pharmaceutically acceptable salt, stereoisomers thereof, a pharmaceutical composition comprising the compound, and a method to treat or prevent neurodegenerative diseases using the compound.
    Type: Application
    Filed: July 19, 2023
    Publication date: November 16, 2023
    Inventors: Jinhwa LEE, Suyeon JO, Keonseung LIM, A Yeong PARK, Jae Eun KIM, Misoon KIM, Seung Mook LIM
  • Patent number: 11802126
    Abstract: The present disclosure provides a compound of Formula (I) or pharmaceutically acceptable salt, stereoisomers thereof, a pharmaceutical composition comprising the compound, and a method to treat or prevent neurodegenerative diseases using the compound.
    Type: Grant
    Filed: July 12, 2021
    Date of Patent: October 31, 2023
    Assignee: 1ST Biotherapeutics, Inc.
    Inventors: Jinhwa Lee, Suyeon Jo, Keonseung Lim, A Yeong Park, Jae Eun Kim, Misoon Kim, Seung Mook Lim
  • Publication number: 20230339978
    Abstract: The present disclosure provides a compound of Formula (I) or pharmaceutically acceptable salt, stereoisomers thereof, a pharmaceutical composition comprising the compound, and a method to treat or prevent inflammatory and autoimmune diseases, especially neuroin-flammation diseases using the compound.
    Type: Application
    Filed: August 20, 2021
    Publication date: October 26, 2023
    Inventors: Jinhwa LEE, Suyeon JO, Jae Eun KIM, Misoon KIM, Inyoung YANG
  • Publication number: 20230339940
    Abstract: The present disclosure relates to [18F]-labeled imidazopyridine derivatives or salts thereof as positron emission tomography (PET) radiotracers suitable for imaging the stress-signaling non-receptor tyrosine kinase c-abl, and their use in in vivo diagnosis, preclinical and clinical imaging, patient stratification on the basis of mutational status of c-abl and assessing response to therapeutic treatments. The present disclosure furtherrelates to the use of [18F]-labeled imidazopyridine derivatives as PET radiotracers. Thedis-closure also provides a process for the radiosynthesis of [18F]-labeled imidazopyridinederivatives.
    Type: Application
    Filed: August 20, 2021
    Publication date: October 26, 2023
    Inventors: Jinhwa LEE, Hwajung NAM
  • Patent number: 11744824
    Abstract: The present disclosure provides a compound of Formula (I) or pharmaceutically acceptable salt, stereoisomers thereof, a pharmaceutical composition comprising the compound, and a method for treating or preventing an inflammatory and autoimmune diseases, especially neuroinflammation diseases using the compound.
    Type: Grant
    Filed: September 14, 2021
    Date of Patent: September 5, 2023
    Assignee: 1ST Biotherapeutics, Inc.
    Inventors: Jinhwa Lee, Suyeon Jo, Keonseung Lim, A Yeong Park, Gadhe Changdev Gorakshnath, Hwajung Nam, Yeonguk Jeon, Yejin Hwang, Jae Eun Kim, Misoon Kim, Inyoung Yang
  • Patent number: 11649255
    Abstract: The present disclosure provides a compound of Formula (I) or pharmaceutically acceptable salts thereof, a composition comprising the compound, methods of using the compound for the treatment of various disorders associated with HPK1, and methods of preparing these compounds.
    Type: Grant
    Filed: September 27, 2021
    Date of Patent: May 16, 2023
    Assignee: 1ST Biotherapeutics, Inc.
    Inventors: Jinhwa Lee, Suyeon Jo, Keonseung Lim, A Yeong Park, Gadhe Changdev Gorakshnath, Hwajung Nam, Yeonguk Jeon, Yejin Hwang, Jae Eun Kim, Misoon Kim, Seung Mook Lim
  • Publication number: 20220242861
    Abstract: The present disclosure provides a compound of Formula (I) or pharmaceutically acceptable salt, stereoisomers thereof, a pharmaceutical composition comprising the compound, and a method to treat or prevent cancer diseases and/or proliferative disorders using the compound.
    Type: Application
    Filed: February 21, 2020
    Publication date: August 4, 2022
    Inventors: Jinhwa LEE, Suyeon JO, Keonseung LIM, A Yeong PARK, Jae Eun KIM, Misoon KIM, Inyoung YANG
  • Publication number: 20220177463
    Abstract: The present disclosure provides polymorphic forms and salts of (1S,2S)-2-fluoro-N-(6-(4-methylpyridin-3-yl)benzo[d]thiazol-2-yl)cyclopropane-1-carboxamide, pharmaceutical compositions comprising the compounds, processes for preparation of the compounds, and methods for treating neurodegenerative disorders.
    Type: Application
    Filed: March 27, 2020
    Publication date: June 9, 2022
    Inventors: Jinhwa LEE, Suyeon JO
  • Publication number: 20220160902
    Abstract: The present disclosure relates to [18F]-labeled benzothiazole derivatives or salts thereof as positron emission tomography (PET) radiotracers suitable for imaging the stress-signaling non-receptor tyrosine kinase c-abl, and their use in in vivo diagnosis, preclinical and clinical imaging, patient stratification on the basis of mutational status of c-abl and assessing response to therapeutic treatments. The present disclosure further relates to the use of [18F]-labeled benzothiazole derivatives as PET radiotracers. The disclosure also provides a process for the radiosynthesis of [18F]-labeled benzothiazole derivatives.
    Type: Application
    Filed: March 6, 2020
    Publication date: May 26, 2022
    Inventors: Jinhwa LEE, Suyeon JO
  • Publication number: 20220098193
    Abstract: The present disclosure provides a compound of Formula (I) or pharmaceutically acceptable salts thereof, a composition comprising the compound, methods of using the compound for the treatment of various disorders associated with HPK1, and methods of preparing these compounds.
    Type: Application
    Filed: September 27, 2021
    Publication date: March 31, 2022
    Inventors: Jinhwa LEE, Suyeon JO, Keonseung LIM, A Yeong PARK, Gadhe Changdev GORAKSHNATH, Hwajung NAM, Yeonguk JEON, Yejin HWANG, Jae Eun KIM, Misoon KIM, Seung Mook LIM
  • Publication number: 20220098219
    Abstract: The present disclosure provides a compound of Formula (I) or pharmaceutically acceptable salts thereof, a composition comprising the compound, methods of using the compound for the treatment of various disorders associated with HPK1, and methods of preparing these compounds.
    Type: Application
    Filed: September 27, 2021
    Publication date: March 31, 2022
    Inventors: Jinhwa LEE, Suyeon JO, Keonseung LIM, A Yeong PARK, Gadhe Changdev GORAKSHNATH, Hwajung NAM, Yeonguk JEON, Yejin HWANG, Jae Eun KIM, Misoon KIM, Seung Mook LIM
  • Publication number: 20220087985
    Abstract: The present disclosure provides a compound of Formula (I) or pharmaceutically acceptable salt, stereoisomers thereof, a pharmaceutical composition comprising the compound, and a method for treating or preventing an inflammatory and autoimmune diseases, especially neuroinflammation diseases using the compound.
    Type: Application
    Filed: September 14, 2021
    Publication date: March 24, 2022
    Inventors: Jinhwa LEE, Suyeon JO, Keonseung LIM, A Yeong PARK, Gadhe Changdev GORAKSHNATH, Hwajung NAM, Yeonguk JEON, Yejin HWANG, Jae Eun KIM, Misoon KIM, Inyoung YANG
  • Publication number: 20210347774
    Abstract: The present disclosure provides a compound of Formula (I) or pharmaceutically acceptable salt, stereoisomers thereof, a pharmaceutical composition comprising the compound, and a method to treat or prevent neurodegenerative diseases using the compound.
    Type: Application
    Filed: July 12, 2021
    Publication date: November 11, 2021
    Inventors: Jinhwa LEE, Suyeon JO, Keonseung LIM, A Yeong PARK, Jae Eun KIM, Misoon KIM, Seung Mook LIM
  • Patent number: 11098044
    Abstract: The present disclosure provides a compound of Formula (I) or pharmaceutically acceptable salt, stereoisomers thereof, a pharmaceutical composition comprising the compound, and a method to treat or prevent neurodegenerative diseases using the compound.
    Type: Grant
    Filed: February 21, 2020
    Date of Patent: August 24, 2021
    Assignee: 1ST Biotherapeutics, Inc.
    Inventors: Jinhwa Lee, Suyeon Jo, Keonseung Lim, A Yeong Park, Jae Eun Kim, Misoon Kim, Seung Mook Lim
  • Patent number: 10968188
    Abstract: The present disclosure provides a compound of general Formula (I) having c-abl kinase inhibitory activity or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the compound, and a method useful to treat or prevent neurodegenerative diseases using the compound.
    Type: Grant
    Filed: May 14, 2020
    Date of Patent: April 6, 2021
    Assignee: 1st Biotherapeutics, Inc.
    Inventors: Jinhwa Lee, Suyeon Jo, A Yeong Park, Gwibin Lee, Jae Eun Kim, Misoon Kim, Gyooseung Jung, Seung Mook Lim, Keonseung Lim, Minwoo Lee, Heekyoung Yang, Hyonam Kim, Hyeongjun Kim, Wanjun Li, Mingzhu Fan
  • Publication number: 20200270246
    Abstract: The present disclosure provides a compound of Formula (I) or pharmaceutically acceptable salt, stereoisomers thereof, a pharmaceutical composition comprising the compound, and a method to treat or prevent neurodegenerative diseases using the compound.
    Type: Application
    Filed: February 21, 2020
    Publication date: August 27, 2020
    Inventors: Jinhwa LEE, Suyeon JO, Keonseung LIM, A Yeong PARK, Jae Eun KIM, Misoon KIM, Seung Mook LIM
  • Publication number: 20200270222
    Abstract: The present disclosure provides a compound of general Formula (I) having c-abl kinase inhibitory activity or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the compound, and a method useful to treat or prevent neurodegenerative diseases using the compound.
    Type: Application
    Filed: May 14, 2020
    Publication date: August 27, 2020
    Inventors: Jinhwa LEE, Suyeon JO, A Yeong PARK, Gwibin LEE, Jae Eun KIM, Misoon KIM, Gyooseung JUNG, Seung Mook LIM, Keonseung LIM, Minwoo LEE, Heekyoung YANG, Hyonam KIM, Hyeongjun KIM, Wanjun LI, Mingzhu FAN
  • Patent number: 10669246
    Abstract: The present disclosure provides a compound of general Formula (I) having c-abl kinase inhibitory activity or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the compound, and a method useful to treat or prevent neurodegenerative diseases using the compound.
    Type: Grant
    Filed: October 1, 2018
    Date of Patent: June 2, 2020
    Assignee: 1ST Biotherapeutics, Inc.
    Inventors: Jinhwa Lee, Suyeon Jo, Gwibin Lee, Keonseung Lim, A Yeong Park, Wanjun Li, Mingzhu Fan